This story first appeared in The Readout newsletter. Sign up for The Readout and receive STAT’s award-winning biotech news ...

GSK confirmed this morning that the disappointing readout from the DREAMM-3 trial of multiple myeloma therapy Blenrep reported earlier this month means that it will take the drug off the US market.

“While President-elect Trump’s alliances may raise the visibility of psychedelics in public health discussions, we are ...

With Eisai and Biogen’s Leqembi and Eli Lilly’s Kisunla launching onto the market, the 2024 Clinical Trials of Alzheimer’s ...